

Ana Garcia-Osta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/634869/publications.pdf>

Version: 2024-02-01

51
papers

3,422
citations

159358

30
h-index

189595

50
g-index

52
all docs

52
docs citations

52
times ranked

4760
citing authors

#	ARTICLE	IF	CITATIONS
1	A critical role for IGF-II in memory consolidation and enhancement. <i>Nature</i> , 2011, 469, 491-497.	13.7	368
2	Phenylbutyrate Ameliorates Cognitive Deficit and Reduces Tau Pathology in an Alzheimer's Disease Mouse Model. <i>Neuropsychopharmacology</i> , 2009, 34, 1721-1732.	2.8	367
3	Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. <i>Hippocampus</i> , 2012, 22, 1040-1050.	0.9	218
4	Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2012, 3, 832-844.	1.7	216
5	Rosiglitazone Rescues Memory Impairment in Alzheimer's Transgenic Mice: Mechanisms Involving a Reduced Amyloid and Tau Pathology. <i>Neuropsychopharmacology</i> , 2010, 35, 1593-1604.	2.8	200
6	Sildenafil restores cognitive function without affecting β -amyloid burden in a mouse model of Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2011, 164, 2029-2041.	2.7	159
7	Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. <i>Neuropharmacology</i> , 2013, 64, 114-123.	2.0	143
8	Amyloid beta mediates memory formation. <i>Learning and Memory</i> , 2009, 16, 267-272.	0.5	141
9	Insulin-like growth factor 2 reverses memory and synaptic deficits in <i>APP</i> transgenic mice. <i>EMBO Molecular Medicine</i> , 2014, 6, 1246-1262.	3.3	114
10	A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice. <i>Neuropsychopharmacology</i> , 2017, 42, 524-539.	2.8	86
11	Decreased levels of guanosine 3',5'-cyclic monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 471-482.	1.8	84
12	MuSK Expressed in the Brain Mediates Cholinergic Responses, Synaptic Plasticity, and Memory Formation. <i>Journal of Neuroscience</i> , 2006, 26, 7919-7932.	1.7	82
13	BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons. <i>NeuroReport</i> , 2001, 12, 919-923.	0.6	73
14	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8967-9004.	2.9	71
15	Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition. <i>Mediators of Inflammation</i> , 2015, 2015, 1-17.	1.4	68
16	Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. <i>Neurobiology of Disease</i> , 2010, 38, 237-245.	2.1	64
17	Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 16, 26-37.	2.3	64
18	Phenylbutyrate is a Multifaceted Drug that Exerts Neuroprotective Effects and Reverses the Alzheimer's Disease-like Phenotype of a Commonly Used Mouse Model. <i>Current Pharmaceutical Design</i> , 2013, 19, 5076-5084.	0.9	59

#	ARTICLE	IF	CITATIONS
19	Chronic Mild Stress Accelerates the Onset and Progression of the Alzheimer's Disease Phenotype in Tg2576 Mice. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 567-578.	1.2	54
20	Differential Regulation by Methylenedioxymethamphetamine of 5-HT _{1A} Receptor Density and mRNA Expression in Rat Hippocampus, Frontal Cortex, and Brainstem: The Role of Corticosteroids. <i>Journal of Neurochemistry</i> , 1997, 68, 1099-1105.	2.1	52
21	Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease. <i>Clinical Epigenetics</i> , 2015, 7, 108.	1.8	52
22	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 506-524.	2.6	48
23	Disrupting the memory of places induced by drugs of abuse weakens motivational withdrawal in a context-dependent manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12345-12350.	3.3	41
24	Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels. <i>Journal of Neurochemistry</i> , 2016, 136, 403-415.	2.1	41
25	Chronic mild stress in mice promotes cognitive impairment and CDK5-dependent tau hyperphosphorylation. <i>Behavioural Brain Research</i> , 2011, 220, 338-343.	1.2	37
26	Current Animal Models of Alzheimer's Disease: Challenges in Translational Research. <i>Frontiers in Neurology</i> , 2014, 5, 182.	1.1	35
27	Dysregulated Postsynaptic Density and Endocytic Zone in the Amygdala of Human Heroin and Cocaine Abusers. <i>Biological Psychiatry</i> , 2011, 69, 245-252.	0.7	32
28	Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 149.	1.7	32
29	Facilitation by 8-OH-DPAT of passive avoidance performance in rats after inactivation of 5-HT _{1A} receptors. <i>British Journal of Pharmacology</i> , 1999, 128, 1691-1698.	2.7	31
30	Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2011, 18, 5545-5553.	1.2	31
31	Epigenetic drugs in Alzheimer's disease. <i>Biomolecular Concepts</i> , 2013, 4, 433-445.	1.0	30
32	Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2017, 8, 638-661.	1.7	30
33	Long-term Phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing A Beta. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 1375-1384.	0.9	29
34	The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 930-941.	0.6	29
35	Discovery of <i>in Vivo</i> Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1765-1782.	1.7	28
36	Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4076-4101.	1.7	27

#	ARTICLE	IF	CITATIONS
37	Phosphodiesterase Inhibition in Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S561-S573.	1.2	24
38	PLA2G4E, a candidate gene for resilience in Alzheimer's disease and a new target for dementia treatment. <i>Progress in Neurobiology</i> , 2020, 191, 101818.	2.8	23
39	Increased CRE-binding activity and tryptophan hydroxylase mRNA expression induced by 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in the rat frontal cortex but not in the hippocampus. <i>Molecular Brain Research</i> , 2004, 126, 181-187.	2.5	22
40	Implanted BDNF-producing fibroblasts prevent neurotoxin-induced serotonergic denervation in the rat striatum. <i>Molecular Brain Research</i> , 2000, 76, 306-314.	2.5	17
41	Synthesis and Evaluation of ¹³ N-Labelled Azo Compounds for β -Amyloid Imaging in Mice. <i>Molecular Imaging and Biology</i> , 2014, 16, 538-549.	1.3	14
42	Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice. <i>Frontiers in Immunology</i> , 2018, 9, 68.	2.2	14
43	GLUT12 Expression in Brain of Mouse Models of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 798-805.	1.9	14
44	Chronic Mild Stress Assay Leading to Early Onset and Propagation of Alzheimer's Disease Phenotype in Mouse Models. <i>Methods in Molecular Biology</i> , 2016, 1303, 241-246.	0.4	13
45	Identifying the Main Functional Pathways Associated with Cognitive Resilience to Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9120.	1.8	13
46	Effect of p-Chloroamphetamine on 5-HT1A and 5-HT7 Serotonin Receptor Expression in Rat Brain. <i>Journal of Neurochemistry</i> , 2008, 74, 1790-1797.	2.1	10
47	Amyloid-Driven Tau Accumulation on Mitochondria Potentially Leads to Cognitive Deterioration in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11950.	1.8	7
48	Reduced basal and phencyclidine-induced expression of heat shock protein-70 in rat prefrontal cortex by the atypical antipsychotic abaperidone. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 31-36.	2.5	5
49	Advanced Assay Monitoring APP-Carboxyl-Terminal Fragments as Markers of APP Processing in Alzheimer Disease Mouse Models. <i>Methods in Molecular Biology</i> , 2016, 1303, 117-123.	0.4	5
50	Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples. <i>Neurotherapeutics</i> , 2018, 15, 742-750.	2.1	5
51	Linking histone deacetylases and phosphodiesterase 5 in novel treatments for Alzheimer's disease. , 2020, , 213-226.		0